<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178436</url>
  </required_header>
  <id_info>
    <org_study_id>2013-133</org_study_id>
    <secondary_id>NCI-2014-01249</secondary_id>
    <secondary_id>1403012942</secondary_id>
    <secondary_id>2013-133</secondary_id>
    <secondary_id>P30CA022453</secondary_id>
    <nct_id>NCT02178436</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase Ib Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330), Gemcitabine and Nab-Paclitaxel and Phase II Study of Gemcitabine and Selinexor in Patients With Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Barbara Ann Karmanos Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized phase Ib/II trial studies the side effects and best dose of&#xD;
      selinexor when given together with gemcitabine and nab-paclitaxel, and to see how well they&#xD;
      work in treating patients with pancreatic cancer that has spread to other parts of the body&#xD;
      (metastatic). Drugs used in chemotherapy, such as selinexor, gemcitabine and nab-paclitaxel,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells, by&#xD;
      stopping them from dividing, or by stopping them from spreading.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        1. Phase I: To determine the recommended phase 2 dose (RP2D) of gemcitabine, nabpaclitaxel&#xD;
           and selinexor for untreated metastatic pancreatic cancer [COMPLETED]&#xD;
&#xD;
        2. Phase I: To determine the safety profile of gemcitabine, nab-paclitaxel and selinexor&#xD;
           [COMPLETED]&#xD;
&#xD;
        3. Phase II: To test whether the combination of gemcitabine and selinexor improves the&#xD;
           median overall survival of patients with metastatic pancreatic cancer who have failed&#xD;
           frontline non-gemcitabine containing regimens beyond 5.6 months (median overall survival&#xD;
           of patient receiving gemcitabine only based on historical data.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        1. To determine objective response rate to the combination of gemcitabine and selinexor&#xD;
           using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.&#xD;
&#xD;
        2. To assess safety of selinexor in combination with gemcitabine in phase II portion of the&#xD;
           study&#xD;
&#xD;
        3. To determine progression free survival (PFS) in patients treated with gemcitabine and&#xD;
           selinexor&#xD;
&#xD;
        4. To determine the influence of selinexor and gemcitabine on the nuclear expression and&#xD;
           localization of tumor suppressor gene proteins.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2014</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase I is completed, due to Dose Limiting Toxicities (DLT).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of selinexor, gemcitabine hydrochloride, and paclitaxel albumin-stabilized nanoparticle formulation combination (Phase Ib)</measure>
    <time_frame>28 days</time_frame>
    <description>MTD is defined as the lowest dose for which less than a third of patients experience a dose limiting toxicity graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of toxicity graded according to NCI CTCAE version 4.03 (Phase II)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Point and 90% Wilson's confidence intervals will be estimated to describe toxicity rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival (Phase II)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed at least one 4-week treatment cycle) using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects the study drug combination has on participants</measure>
    <time_frame>Day 1 of course 1 (before selinexor administration, 1, 2, 4 and 8 hours after selinexor administration) and days 2, 3 and 8</time_frame>
    <description>Pharmacodynamics of selinexor in combination with gemcitabine hydrochloride and paclitaxel albumin-stabilized nanoparticle formulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Point and 90% Wilson's confidence intervals will be estimated to describe response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (Phase II)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Estimated on an intention-to-treat basis (using all registered patients), and on a response-evaluable basis (using all patients who completed at least one 4-week treatment cycle) using the Kaplan-Meier method.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in gene expression (including forkhead box protein O, I-kappaB, cyclin-dependent kinase inhibitor 1B, Par4 and phosphorylated signal transducer and activator of transcription 3) (Phase II)</measure>
    <time_frame>Baseline to up to 2 years</time_frame>
    <description>Seven patients in each group will yield a two-sided 90% confidence interval with a distance from the mean change to the limits of 0.75 standard deviation units. A two-sided p-value of 0.10 will be used for all analyses.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Acinar Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Duct Cell Adenocarcinoma of the Pancreas</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV, nab-paclitaxel IV, and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II: Phase II Group I (gemcitabine, selinexor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV on days 1, 8, and 15. Patients also receive selinexor PO on days 3, 8, and 15 of cycle 1 and on days 1, 8, and 15 for the subsequent cycles. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GroupIII: Phase II Group II (gemcitabine, selinexor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine hydrochloride IV and selinexor PO on days 1, 8, and 15. Cycles repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)</arm_group_label>
    <arm_group_label>Group II: Phase II Group I (gemcitabine, selinexor)</arm_group_label>
    <arm_group_label>GroupIII: Phase II Group II (gemcitabine, selinexor)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>Gemcitabine HCI</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selinexor</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)</arm_group_label>
    <arm_group_label>Group II: Phase II Group I (gemcitabine, selinexor)</arm_group_label>
    <arm_group_label>GroupIII: Phase II Group II (gemcitabine, selinexor)</arm_group_label>
    <other_name>KPT-330</other_name>
    <other_name>Xpovio</other_name>
    <other_name>CRM1 nuclear export inhibitor KPT-330</other_name>
    <other_name>selective inhibitor of nuclear export KPT-330</other_name>
    <other_name>SINE KPT-330</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)</arm_group_label>
    <arm_group_label>Group II: Phase II Group I (gemcitabine, selinexor)</arm_group_label>
    <arm_group_label>GroupIII: Phase II Group II (gemcitabine, selinexor)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)</arm_group_label>
    <arm_group_label>Group II: Phase II Group I (gemcitabine, selinexor)</arm_group_label>
    <arm_group_label>GroupIII: Phase II Group II (gemcitabine, selinexor)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I: Phase Ib (gemcitabine, nab-paclitaxel, selinexor)</arm_group_label>
    <other_name>ABI 007</other_name>
    <other_name>Abraxane</other_name>
    <other_name>Protein-bound Paclitaxel</other_name>
    <other_name>Nanoparticle Paclitaxel,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent in accordance with federal, local, and institutional&#xD;
             guidelines&#xD;
&#xD;
          -  Patients with metastatic pancreatic adenocarcinoma not treated with chemotherapy for&#xD;
             metastatic disease&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin &lt; 2 times the upper limit of normal (ULN) (except patients with Gilbert's&#xD;
             syndrome who must have a total bilirubin of &lt; 3 times ULN)&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) &lt; 2.5 times ULN&#xD;
&#xD;
          -  Serum creatinine =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  Serum albumin &gt;= 3.0 g/dL&#xD;
&#xD;
          -  Female patients of child-bearing potential must agree to use dual methods of&#xD;
             contraception and have a negative serum pregnancy test at screening, and male patients&#xD;
             must use an effective barrier method of contraception if sexually active with a female&#xD;
             of child-bearing potential; acceptable methods of contraception are condoms with&#xD;
             contraceptive foam, oral, implantable or injectable contraceptives, contraceptive&#xD;
             patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is&#xD;
             surgically sterilized or post-menopausal; for both male and female patients, effective&#xD;
             methods of contraception must be used throughout the study and for three months&#xD;
             following the last dose&#xD;
&#xD;
          -  Patients with history of previously treated malignancies who have no evidence of&#xD;
             disease for last five years are allowed to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are pregnant or lactating&#xD;
&#xD;
          -  Radiation, chemotherapy, or immunotherapy or any other anticancer therapy =&lt; 3 weeks&#xD;
             prior to cycle 1 day 1; mitomycin C or radio-immunotherapy 6 weeks prior to cycle 1&#xD;
             day 1&#xD;
&#xD;
          -  Major surgery within four weeks before cycle 1 day 1&#xD;
&#xD;
          -  Unstable cardiovascular function:&#xD;
&#xD;
               -  Symptomatic ischemia, or&#xD;
&#xD;
               -  Uncontrolled clinically significant conduction abnormalities (e.g.: ventricular&#xD;
                  tachycardia on antiarrhythmics are excluded and 1st degree atrioventricular [AV]&#xD;
                  block or asymptomatic left anterior fascicular block [LAFB]/right bundle branch&#xD;
                  block [RBBB] will not be excluded), or&#xD;
&#xD;
               -  Congestive heart failure (CHF) of New York Heart Association (NYHA) class &gt;= 3,&#xD;
                  or&#xD;
&#xD;
               -  Myocardial infarction (MI) within 3 months of cycle 1 day 1 dose&#xD;
&#xD;
          -  Uncontrolled active infection requiring parenteral antibiotics, antivirals, or&#xD;
             antifungals within one week prior to first dose&#xD;
&#xD;
          -  Known to be HIV seropositive who are on anti-HIV drugs because of the unknown&#xD;
             interactions between these drugs and the study agents&#xD;
&#xD;
          -  Known active hepatitis A, B, or C infection; or known to be positive for hepatitis C&#xD;
             virus (HCV) ribonucleic acid (RNA) or HBsAg (hepatitis B virus [HBV] surface antigen)&#xD;
&#xD;
          -  Patients with active central nervous system (CNS) malignancy; asymptomatic small&#xD;
             lesions are not considered active; treated lesions may be considered inactive if they&#xD;
             are stable for at least 3 months&#xD;
&#xD;
          -  Patients with significantly diseased or obstructed gastrointestinal tract or&#xD;
             uncontrolled vomiting or diarrhea&#xD;
&#xD;
          -  Grade &gt;= 2 peripheral neuropathy within 14 days prior to cycle 1 day 1&#xD;
&#xD;
          -  History of seizures, movement disorders or cerebrovascular accident within the past 5&#xD;
             years prior to cycle 1 day 1&#xD;
&#xD;
          -  Patients with muscular degeneration, uncontrolled glaucoma, or markedly decreased&#xD;
             visual acuity based on physician's assessment&#xD;
&#xD;
          -  Serious psychiatric or medical conditions that could interfere with treatment&#xD;
&#xD;
          -  Participation in an investigational anti-cancer study within 3 weeks prior to cycle 1&#xD;
             day 1&#xD;
&#xD;
          -  Concurrent therapy with approved or investigational anticancer therapeutic&#xD;
&#xD;
          -  Presence of clinically significant ascites&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip Philip</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barbara Ann Karmanos Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anup Kasi, M.D.</last_name>
      <phone>913-588-6029</phone>
      <email>akasi@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip A. Philip</last_name>
      <phone>313-576-8728</phone>
      <email>philipp@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Philip A. Philip, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Shields, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Naieb Al Hallak, M.D., MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Cancer Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Minsig Choi, M.D.</last_name>
      <phone>631-444-3578</phone>
      <email>minsig.choi@stonybrookmedicine.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mandana Kamgar, M.D.</last_name>
      <phone>414-805-4600</phone>
      <email>mkamgar@mcw.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>June 23, 2014</study_first_submitted>
  <study_first_submitted_qc>June 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Barbara Ann Karmanos Cancer Institute</investigator_affiliation>
    <investigator_full_name>Philip Philip</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Acinar Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

